Michael J. Pontecorvo
Corporate Officer/Principal chez Avid Radiopharmaceuticals, Inc.
Profil
Michael J.
Pontecorvo is currently the Vice President of Clinical Development at Avid Radiopharmaceuticals, Inc. He previously worked as the Vice President of Clinical Research at DOV Pharmaceutical, Inc. and as a Principal at Janssen Pharmaceutica NV.
He obtained his undergraduate degree from Indiana University.
Postes actifs de Michael J. Pontecorvo
| Sociétés | Poste | Début |
|---|---|---|
Avid Radiopharmaceuticals, Inc.
 Avid Radiopharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Avid Radiopharmaceuticals, Inc. provides molecular imaging services. It develops new molecular imaging agents capable of changing the medical management of significant, chronic human diseases by identifying the first stages of pathological change, potentially assisting in earlier diagnosis, and better management and development of new therapies. The company was founded by Daniel M. Skovronsky in 2004 and is headquartered in Philadelphia, PA. | Corporate Officer/Principal | - |
Anciens postes connus de Michael J. Pontecorvo
| Sociétés | Poste | Fin |
|---|---|---|
DOV Pharmaceutical, Inc.
 DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | Directeur Technique/Scientifique/R&D | - |
Janssen Pharmaceutica NV
 Janssen Pharmaceutica NV Pharmaceuticals: MajorHealth Technology Janssen Pharmaceutica NV engages in the development of medical solutions. It offers research and development services in the field of mental illness, neurological disorders, anesthesia, analgesia, gastrointestinal disorders, fungal infection, allergies and cancer. The firms products include Zytiga, Caelyx, Dacogen, Edurant, Fentanyl-Janssen, Intelence, Leustatin, , Pariet, and Reminyl. The company was founded in 1953 by Paul Janssen and is headquartered in Beerse, Belgium. | Corporate Officer/Principal | - |
Formation de Michael J. Pontecorvo
| Indiana University | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Avid Radiopharmaceuticals, Inc.
Avid Radiopharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Avid Radiopharmaceuticals, Inc. provides molecular imaging services. It develops new molecular imaging agents capable of changing the medical management of significant, chronic human diseases by identifying the first stages of pathological change, potentially assisting in earlier diagnosis, and better management and development of new therapies. The company was founded by Daniel M. Skovronsky in 2004 and is headquartered in Philadelphia, PA. | Health Services |
Janssen Pharmaceutica NV
Janssen Pharmaceutica NV Pharmaceuticals: MajorHealth Technology Janssen Pharmaceutica NV engages in the development of medical solutions. It offers research and development services in the field of mental illness, neurological disorders, anesthesia, analgesia, gastrointestinal disorders, fungal infection, allergies and cancer. The firms products include Zytiga, Caelyx, Dacogen, Edurant, Fentanyl-Janssen, Intelence, Leustatin, , Pariet, and Reminyl. The company was founded in 1953 by Paul Janssen and is headquartered in Beerse, Belgium. | Health Technology |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | Commercial Services |
